A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
Eligibility criteria
Qualifiers
Diffuse pleural mesothelioma (DPM)
Gastroesophageal carcinoma (GEC) including adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach.
PD-L1 CPS ≥1 (using clone 73-10, DAKO)
HER2 overexpression negative (using clone 4B5, Ventana): HER2 IHC 0-1+, or HER2 2+ with ISH showing HER2:CEP17 ratio <2 and average HER2 copy number <6.0 signals/cell
Disqualifiers
Prior treatment with PRMT5i or MAT2Ai
Symptomatic CNS metastases
Patients with treated brain metastases are eligible if follow up brain imaging after CNS directed therapy shows no evidence of progression and the patient is on a stable dose of corticosteroids
Received palliative radiation therapy within 3 days prior to initiation of study treatment or definitive SRS including CNS SRS within 14 days prior to initiation of study treatment
Trial design
Treatments tested in this trial
- BMS-986504
- Ipilimumab
- Nivolumab
- 5-FU
- Leucovorin
- Oxaliplatin
- Gemcitabine
- Platinum
Treatment groups
60 Participants
are divided into 3 treatment groupsSponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov